Stock Detail
OPKO HEALTH INC
Sector: Biotechnology
Latest Quote @ Wed May 5 07:46:31 (15 min delayed)
| $5.12 |
$9.69 |
$6.94 |
-0.06 |
-0.86% |
1.16M |
Last Day's Data
| $6.94 |
$7.11 |
$0.00 |
0.00% |
0.00 |
$7.00 |
| $7.05 |
$6.92 |
1.00 |
2.34B |
1.55M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 7.18 |
7.06 |
6.99 |
6.87 |
6.80 |
Stock Profile
Opko Health, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment and prevention of ophthalmic disorders and diseases. Its product candidates include bevasiranib sodium, which completed a Phase II clinical trial for the treatment of wet age-related macular degeneration (Wet AMD) and diabetic macular edema. The company is also developing product candidates for the treatment of Wet AMD, which target other pathways involved in the pathogenesis of Wet AMD, including hypoxia-inducible factor 1 alpha. In addition, it is developing products for the treatment of dry age-related macular degeneration and retinitis pigmentosa diseases. Opko Health has collaboration and license agreements with University of Pennsylvania, Intradigm Corporation, Pathogenics, Inc., University of Illinois, ZaBeCor Pharmaceutical Company, LLC, and University of Florida Research Foundation. The company was founded in 2006 and is based in Miami, Florida.
